117 related articles for article (PubMed ID: 38453260)
1. Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents.
Nakka S; Raza A; Chaitanya KS; Bandaru NVMR; Chandu A; Murugesan S; Devunuri N; Sharma AK; Chandrasekhar KVG
Chem Biol Drug Des; 2024 Mar; 103(3):e14502. PubMed ID: 38453260
[TBL] [Abstract][Full Text] [Related]
2. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
3. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
4. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
5. Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study.
Mohamady S; Khalil AF; Naguib BH; Nafie MS; Tawfik HO; Shaldam MA
Bioorg Chem; 2024 Feb; 143():106988. PubMed ID: 37995644
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
[TBL] [Abstract][Full Text] [Related]
7. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 3-N-/O-/S-methyl-imidazo[1,2-a] pyridine derivatives for caspase-3 mediated apoptosis induced anticancer activity.
Singh D; Yodun T; Kumar G; Ahmad Tali J; Tiwari H; Singh J; Nargotra A; Samykutty A; Singh S; Shankar R
Bioorg Chem; 2022 Aug; 125():105882. PubMed ID: 35660838
[TBL] [Abstract][Full Text] [Related]
12. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, cytotoxicity, apoptosis and molecular docking studies of novel phenylbutyrate derivatives as potential anticancer agents.
Mostoufi A; Baghgoli R; Fereidoonnezhad M
Comput Biol Chem; 2019 Jun; 80():128-137. PubMed ID: 30952039
[TBL] [Abstract][Full Text] [Related]
14. Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors.
Rezaei Z; Mahdi Didehvar M; Mahdavi M; Azizian H; Hamedifar H; Mohammed EHM; Ostad S; Amini M
Bioorg Chem; 2019 Sep; 90():103055. PubMed ID: 31220669
[TBL] [Abstract][Full Text] [Related]
15. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.
Murahari M; Prakash KV; Peters GJ; Mayur YC
Eur J Med Chem; 2017 Oct; 139():961-981. PubMed ID: 28886509
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents and caspase-3/7 activators.
Al-Oudat BA; Alqudah MA; Audat SA; Al-Balas QA; El-Elimat T; Hassan MA; Frhat IN; Azaizeh MM
Drug Des Devel Ther; 2019; 13():423-433. PubMed ID: 30774307
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
18. Introducing novel potent anticancer agents of 1H-benzo[f]chromene scaffolds, targeting c-Src kinase enzyme with MDA-MB-231 cell line anti-invasion effect.
Ahmed HEA; El-Nassag MAA; Hassan AH; Okasha RM; Ihmaid S; Fouda AM; Afifi TH; Aljuhani A; El-Agrody AM
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1074-1088. PubMed ID: 29923425
[TBL] [Abstract][Full Text] [Related]
19. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation.
Yevale DB; Teraiya N; Lalwani TD; Ameta RK; Sangani CB
Bioorg Chem; 2023 Dec; 141():106901. PubMed ID: 37797455
[TBL] [Abstract][Full Text] [Related]
20. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
